A New Drug Approval- Erleada ™ (apalutamide) For Non-Metastatic Castration-Resistant Prostate Cancer

he FDA approved a new advanced hormone therapy drug (a next-generation androgen receptor inhibitor) for the treatment of men with non-metastatic castration-resistant prostate cancer (NM-CRPC). This drug with the trade name Erleada (aka apalutamide), is the first drug approved in this disease space. 

The FDA Approves Abiraterone Acetate for Some Men with Castrate Sensitive Metastatic Prostate Cancer

The Food and Drug Administration approved the use of abiraterone acetate (Zytiga) with prednisone for men with high-risk, castration-sensitive, chemotherapy-naive metastatic prostate cancer, but there are some hitches and hurdles.

New Standard of Care for Men With Non-Metastatic Castrate Resistant Prostate Cancer 

Two different trials, SPARTAN and PROSPER, are reporting top-line results in the treatment of men with nmCRPC. The full results of these trials will be presented today at the Genitourinary Cancer Symposium in San Francisco where Cancer ABCs is in attendance.

Xofigo Probably Can Be Used More Than Once

Early results from an international, open-label, phase 1/2 trial (NCT01934790) showed that it is possible to successfully re-treat men with the drug known as Xofigo (Ra-223).  The study found that when used a second time, Xofigo was well tolerated and that it provides favorable effects on the cancer’s progression.  

The EU Imposes Restrictions On The Use Of Gadolinium As A Contrast Agent In MRIs

The European Union has recently placed some restrictions on the use of the MRI contrast agent Gadolinium.  There has been concern expressed by recent findings that Gadolinium doesn’t wholly disappear or wash out of a person’s body, but instead stays in a person’s brain.

Confirming The Value of Early Docetaxel in Men With Metastatic Hormone-Sensitive Prostate Cancer

Docetaxel combined with ADT, in men with hormone sensitive prostate cancer, when prescribed as per a study’s protocol led to significantly longer overall survival as well as other positive effects in men with metastatic hormone-sensitive prostate cancer who received only ADT. 

FOUNDATION ONE CDx – A NEW BROAD BRUSH GENETIC TEST TO HELP MAKE BETTER TREATMENT DECISIONS

Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.